Life Science REIT PLC
LSE:LABS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Life Science REIT PLC
Cost of Revenue
Life Science REIT PLC
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
Life Science REIT PLC
LSE:LABS
|
Cost of Revenue
-£5.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Primary Health Properties PLC
LSE:PHP
|
Cost of Revenue
-£27m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-41%
|
|
|
Assura PLC
LSE:AGR
|
Cost of Revenue
-£16.7m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
Target Healthcare REIT PLC
LSE:THRL
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Life Science REIT PLC
Glance View
Life Science Reit Plc is an investment company, which intends to carry on business as a REIT. The Company’s investment objective is to provide shareholders with a level of total return. The company will seek to achieve its investment objective by investing in a diversified portfolio of properties across the United Kingdom which are leased or intended to be leased to tenants operating in, or providing a benefit to, the life science sector. The company acquires or develops properties, such as wet and dry laboratories, offices, incubators and co-working space, manufacturing and testing facilities and data centers. The company acquires individual buildings, a group of buildings across a single science park or the entirety of a science park. This may include purchasing or developing buildings that are leased or intended to be leased to tenants providing ancillary services to employees of companies operating in, or providing a benefit to, the life science sector. The Company’s investment adviser is Ironstone Asset Management Limited.
See Also
What is Life Science REIT PLC's Cost of Revenue?
Cost of Revenue
-5.9m
GBP
Based on the financial report for Dec 31, 2024, Life Science REIT PLC's Cost of Revenue amounts to -5.9m GBP.
What is Life Science REIT PLC's Cost of Revenue growth rate?
Cost of Revenue CAGR 1Y
4%
Over the last year, the Cost of Revenue growth was 4%.